Trivitron Healthcare acquires the USA based The Kennedy Company

Trivitron Healthcare, a global medical technology company, has acquired 100% shareholding in the USA based, The Kennedy Company, a leading manufacturer of Radiation Protection X-ray Shielding Material and Acoustic Barrier Products.

Trivitron Healthcare is committed to providing research-driven technologically advanced yet affordable healthcare products and with this acquisition, the company has further strengthened its manufacturing presence in the USA.

The Kennedy Company was founded in 1976, by Mr. David R. Kennedy, a physicist educated at University of London. While he was employed on the Saturn Rocket Project at the Space Technology Centre in Huntsville, he worked on developing innovative acoustic barriers for NASA.

The Kennedy Company’s 7 acres cutting-edge Technology Park in Scottsboro, Alabama will soon house multiple manufacturing and R&D facilities focusing on Trivitron’s core segments – Medical Imaging, IVD, ICU and Cardiology Equipment & Consumables.

Commenting on the acquisition, Dr. GSK Velu, Chairman & Managing Director, Trivitron said, “We are immensely pleased to welcome The Kennedy Company into the Trivitron Group. We intend to further strengthen the robust foundation created by Mr. David Kennedy and his team with Trivitron’s global presence, infrastructure, and robust manufacturing. With this acquisition, Trivitron will now have a manufacturing and R&D presence in India, USA, Finland, Turkey, China and Austria.”

Mr. Satyaki Banerjee, CEO – Medical Imaging, Trivitron Healthcare commented, “By augmenting the manufacturing experience of the Kennedy team with deep technical know-how and regulatory focus of Trivitron, we can offer the widest selection of Radiation Protection and Medical Imaging Products globally.”

“We are delighted to join the Trivitron Group. I am confident that this merger will benefit both of us and the greater Huntsville area provides the perfect backdrop to expand skilled manufacturing,” said Mr. David R. Kennedy, Founder, The Kennedy Company.

Post integration, the new entity would become a part of Trivitron Healthcare Americas, operating as Kennedy Vinyl for the existing X-ray Shielding and Acoustic Noise Control business and Kennedy Radiology for Radiation Protection Products manufactured in the USA.

The organization would be led by Mr. Sesh Sarathy, who spearheaded Trivitron Group’s M&A efforts in North America, as President, Sales and Business Development, and Mrs. Sarah Kennedy Precise, who’s been a part of the Kennedy team for more than two decades, as President, Operations.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version